Here are the S-3 shelf registrations from Avalo Therapeutics, Inc. (AVTX) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An S-3 covers the shelf registration that lets an established company sell over time, so if you follow AVTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AVTX filings page.
Avalo Therapeutics, Inc. filed an automatic shelf registration covering common stock, preferred stock, debt securities, warrants and/or units. Avalo and/or selling stockholders may offer securities from time to time after effectiveness, with specific terms and amounts described in a prospectus supplement. Avalo says it will receive no proceeds from selling-stockholder sales; net proceeds from its own sales are intended for general corporate purposes, including clinical trials, research and development, and general and administrative expenses, unless a supplement states otherwise.
Avalo describes abdakibart as advancing into a Phase 3 registrational program for hidradenitis suppurativa and reports that Phase 2 LOTUS met its primary endpoint at both tested doses. The prospectus states 42.2% and 42.9% absolute improvement in HiSCR75 response rates at Week 16 for 150 mg and 300 mg, respectively, and 42.5% combined, versus a 25.6% placebo rate.
Avalo Therapeutics, Inc. has filed a resale registration covering up to 128,189 shares of common stock held by former AlmataBio, Inc. stockholders. These shares were issued under a Milestone Buyout Option Agreement and Amendment to the merger agreement with AlmataBio.
The registration enables the selling stockholders to sell their shares from time to time; Avalo is not selling any shares and will not receive proceeds from these resales, though it will bear registration expenses. The shares may be sold through various methods at prices based on the market price of Avalo’s Nasdaq‑listed stock (symbol AVTX; last reported price $17.88 per share on July 16, 2026).
Avalo is a clinical‑stage biotechnology company focused on IL‑1β‑targeted therapies. Its lead antibody, abdakibart (AVTX‑009), met the primary endpoint in the Phase 2 LOTUS trial in hidradenitis suppurativa, with 253 adults enrolled and statistically significant HiSCR75 responses at both doses. Based on these data, the company plans to advance abdakibart into a registrational Phase 3 program.
Avalo Therapeutics, Inc. has filed a shelf registration statement that allows it to offer up to $750,000,000 of common stock, preferred stock, debt securities, warrants and units from time to time. The filing also carries forward $326,585,963 of previously registered but unsold securities from an expiring shelf under SEC Rule 415(a)(6), so those amounts remain available without interruption. Proceeds from future offerings may be used for general corporate purposes, including clinical trials, research and development, and general and administrative expenses. Avalo is a clinical-stage biotechnology company focused on IL‑1β-based therapies, led by AVTX‑009 in a Phase 2 trial for hidradenitis suppurativa, with topline data expected in the second quarter of 2026.